Abstract:BACKGROUND Therapy for metastatic kidney cancer is actively evolving, particularly in the results of registration drug trials that have led to the approval of vascular endothelial growth factor pathway drugs such as sorafenib, sunitinib, pazopanib, bevacizumab, and axitinib, with focus on patients with good- or intermediate-risk criteria and clear cell histology. Mammalian target of rapamycin (mTOR) drugs such as everolimus and temsirolimus pivotal trials emphasize experiences in the setting of prior treatment or high-risk features. Interferon and interleukin 2 also are part of the treatment algorithms. METHODS The results of pivotal trials and the underlying context for the development of a cogent, cohesive treatment plan for an individual are reviewed, touching on decision points such as nephrectomy, metastasectomy, and medical initiation and discontinuation time points. RESULTS To the extent that these drug therapies are essential for achieving best outcomes for patients, these pivotal trial results and associated guidelines exist within a multidimensional, multidisciplinary context of many other disease features, comorbid features, and non-drug treatment decisions. Other dimensions include investigational targeted therapies, patient selection strategies, surgical strategies, and immunotherapies, some of which are in active development. CONCLUSIONS Clinicians should work toward the best use of drug sequencing and selection strategies based on core data derived from prospective randomized trials. To address individual patient needs, they should also recognize and emphasize individualized goals, to the extent that these are different from issues that were directly addressed in the trials.

How to select targeted agents for advanced kidney cancer?

Expert consensus of anti-tumor drugs prescription review: kidney cancer

Analysis of diagnosis and treatment of 109 cases with renal cell carcinoma

Targeted therapy of kidney cancer: keeping the art around the algorithms.

Individualized targeted therapy for advanced renal cell carcinoma

Molecular target agent selection and curative effects for the treatment of advanced renal cell carcinoma with different metastatic sites

Status and progress of targeted therapy of renal cell carcinoma

Targeted therapy of metastatic renal cell carcinoma

The present situation of targeted drug therapy of renal cell carcinoma

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers

Current status and progress in the targeted therapy for advanced renal cell carcinoma

Targeted Drug Delivery Systems for Kidney Diseases

Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review

Nephrotoxicity of targeted therapy used to treat lung cancer

Targeted nanotherapy for kidney diseases: a comprehensive review

Targeted therapy of kidney disease with nanoparticle drug delivery materials

Advances in biological targeted drugs in pancreatic cancer

AKI Associated with Anti-cancer Therapies: Small Molecules and Targeted Therapies

Selection and therapeutic effect evaluation of chemotherapy regimens for pancreatic cancer

Drug design strategies for the treatment of prostate cancer